

# Graham R Foster

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4169305/publications.pdf>

Version: 2024-02-01

231  
papers

18,108  
citations

22099

59  
h-index

13727

129  
g-index

285  
all docs

285  
docs citations

285  
times ranked

17682  
citing authors

#	ARTICLE	IF	CITATIONS
1	Role of peer support in a hepatitis C elimination programme. <i>Journal of Viral Hepatitis</i> , 2022, 29, 43-51.	1.0	8
2	Increased burden of cardiovascular disease in people with liver disease: unequal geographical variations, risk factors and excess years of life lost. <i>Journal of Translational Medicine</i> , 2022, 20, 2.	1.8	12
3	The A150V Polymorphism of Genotype 3 Hepatitis C Virus Polymerase Inhibits Interferon Alfa by Suppressing Protein Kinase R Activation. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 11, 1163-1175.	2.3	1
4	Targeted vs opportunistic screening for viral hepatitis among UK migrant communities: a cost-effectiveness analysis. <i>British Journal of Health Care Management</i> , 2021, 27, 90-98.	0.1	0
5	Disparities of SARS-CoV-2 Nucleoprotein-Specific IgG in Healthcare Workers in East London, UK. <i>Frontiers in Medicine</i> , 2021, 8, 642723.	1.2	10
6	New dimensions for hospital services and early detection of disease: a Review from the Lancet Commission into liver disease in the UK. <i>Lancet, The</i> , 2021, 397, 1770-1780.	6.3	18
7	Improving care transfers for homeless patients after hospital discharge: a realist evaluation. <i>Health Services and Delivery Research</i> , 2021, 9, 1-186.	1.4	5
8	Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure. <i>Nature Communications</i> , 2021, 12, 6105.	5.8	11
9	Cost-Effectiveness Analysis of Baseline Testing for Resistance-Associated Polymorphisms to Optimize Treatment Outcome in Genotype 1 Noncirrhotic Treatment-Naïve Patients With Chronic Hepatitis C Virus. <i>Value in Health</i> , 2020, 23, 180-190.	0.1	1
10	Unacceptable failures: the final report of the Lancet Commission into liver disease in the UK. <i>Lancet, The</i> , 2020, 395, 226-239.	6.3	53
11	Estimated impact of the COVID-19 pandemic on cancer services and excess 1-year mortality in people with cancer and multimorbidity: near real-time data on cancer care, cancer deaths and a population-based cohort study. <i>BMJ Open</i> , 2020, 10, e043828.	0.8	233
12	Hepatosplenic schistosomiasis in Zambian adults is characterized by increased liver stiffness: A nested case-control study. <i>Heliyon</i> , 2020, 6, e04534.	1.4	5
13	Stat2 loss disrupts damage signalling and is protective in acute pancreatitis. <i>Journal of Pathology</i> , 2020, 252, 41-52.	2.1	3
14	Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B. <i>PLoS ONE</i> , 2020, 15, e0230893.	1.1	2
15	English hepatitis C registry data show high response rates to directly acting antivirals, even if treatment is not completed. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 168-181.	1.9	8
16	Amino Acid Substitutions in Genotype 3a Hepatitis C Virus Polymerase Protein Affect Responses to Sofosbuvir. <i>Gastroenterology</i> , 2019, 157, 692-704.e9.	0.6	27
17	VIRAL LOAD AND NUCLEOTIDE SUBSTITUTIONS IN HEPATITIS B VIRUSES DERIVED FROM CHRONIC HBV PATIENTS. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019, 11, e2019046.	0.5	1
18	Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) – a natural experiment (protocol). <i>BMJ Open</i> , 2019, 9, e029538.	0.8	30

#	ARTICLE	IF	CITATIONS
19	Consensus recommendations for resistance testing in the management of chronic hepatitis C virus infection: Public Health England HCV Resistance Group. <i>Journal of Infection</i> , 2019, 79, 503-512.	1.7	23
20	The Hepatitis C Awareness Through to Treatment (HepCATT) study: improving the cascade of care for hepatitis C virus-infected people who inject drugs in England. <i>Addiction</i> , 2019, 114, 1113-1122.	1.7	33
21	The association between hepatocellular carcinoma and direct-acting anti-viral treatment in patients with decompensated cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 204-214.	1.9	20
22	Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180Âmg and uprifosbuvir 450Âmg for 12Âweeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1127-1138.	1.0	10
23	A Cost-Effectiveness Analysis of Shortened Direct-Acting Antiviral Treatment in Genotype 1 Noncirrhotic Treatment-Naive Patients With Chronic Hepatitis C Virus. <i>Value in Health</i> , 2019, 22, 693-703.	0.1	13
24	Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection. <i>Journal of Gastroenterology</i> , 2019, 54, 752-761.	2.3	17
25	Genetic variation in <i>FCER1A</i> predicts peginterferon alfa-2a-induced hepatitis B surface antigen clearance in East Asian patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1040-1049.	1.0	3
26	Improving engagement with healthcare in hepatitis C: a randomised controlled trial of a peer support intervention. <i>BMC Medicine</i> , 2019, 17, 71.	2.3	46
27	Persistent fatigue induced by interferon-alpha: a novel, inflammation-based, proxy model of chronic fatigue syndrome. <i>Psychoneuroendocrinology</i> , 2019, 100, 276-285.	1.3	62
28	Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older. <i>PLoS ONE</i> , 2019, 14, e0208506.	1.1	29
29	Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studies. <i>Drug and Alcohol Dependence</i> , 2019, 194, 487-494.	1.6	33
30	Case finding and therapy for chronic viral hepatitis in primary care (HepFREE): a cluster-randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 32-44.	3.7	22
31	Seroprevalence and demographic factors associated with hepatitis B, hepatitis C and HIV infection from a hospital emergency department testing programme, London, United Kingdom, 2015 to 2016. <i>Eurosurveillance</i> , 2019, 24, .	3.9	8
32	Interferon lambda 4 impacts the genetic diversity of hepatitis C virus. <i>ELife</i> , 2019, 8, .	2.8	28
33	Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial. <i>Hepatology</i> , 2018, 67, 2113-2126.	3.6	22
34	Autoantibody to apolipoprotein A-1 in hepatitis C virus infection: a role in atherosclerosis?. <i>Hepatology International</i> , 2018, 12, 17-25.	1.9	11
35	Reply to: "Reply to: Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries". <i>Journal of Hepatology</i> , 2018, 68, 864-866.	1.8	2
36	Glecaprevir/Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. <i>New England Journal of Medicine</i> , 2018, 378, 354-369.	13.9	361

#	ARTICLE	IF	CITATIONS
37	Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes. <i>Clinical Infectious Diseases</i> , 2018, 66, 1742-1750.	2.9	21
38	Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy001.	0.4	36
39	Non-invasive markers of liver fibrosis in fatty liver disease are unreliable in people of South Asian descent. <i>Frontline Gastroenterology</i> , 2018, 9, 115-121.	0.9	23
40	High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1 patients without cirrhosis. <i>Journal of Hepatology</i> , 2018, 69, 293-300.	1.8	127
41	Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 125-133.	3.7	128
42	Disease burden and costs from excess alcohol consumption, obesity, and viral hepatitis: fourth report of the Lancet Standing Commission on Liver Disease in the UK. <i>Lancet</i> , 2018, 391, 1097-1107.	6.3	140
43	Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1 and compensated cirrhosis or advanced fibrosis. <i>Liver International</i> , 2018, 38, 443-450.	1.9	40
44	IDDF2018-ABS-0113...The safety and tolerability of sof/vel/vox for 8 or 12 weeks in >1,000 patients treated in the polaris-1, polaris-2, polaris-3, and polaris-4 studies: an integrated analysis. , 2018, , .		0
45	Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy248.	0.4	5
46	Third-generation ventricular assist devices. , 2018, , 151-186.		8
47	Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 626-634.	3.7	103
48	Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation. <i>Journal of Clinical Investigation</i> , 2018, 128, 668-681.	3.9	167
49	Chronic hepatitis B virus mono-infection at a university hospital in Zambia. <i>World Journal of Hepatology</i> , 2018, 10, 622-628.	0.8	4
50	Rifaximin Reduces Markers of Inflammation and Bacterial 16S rRNA in Zambian Adults with Hepatosplenic Schistosomiasis: A Randomized Control Trial. <i>American Journal of Tropical Medicine and Hygiene</i> , 2018, 98, 1152-1158.	0.6	3
51	Improving Hospital Discharge Arrangements for People who are Homeless: The Role of Specialist Integrated Care. <i>International Journal of Integrated Care</i> , 2018, 18, 18.	0.1	4
52	Chronic hepatitis C: less of a problem than first thought?. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 146-147.	3.7	4
53	Defective monocyte oxidative burst predicts infection in alcoholic hepatitis and is associated with reduced expression of NADPH oxidase. <i>Gut</i> , 2017, 66, 519-529.	6.1	54
54	Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus. <i>Nature Genetics</i> , 2017, 49, 666-673.	9.4	129

#	ARTICLE	IF	CITATIONS
55	Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials. <i>Gastroenterology</i> , 2017, 153, 113-122.	0.6	215
56	Chronic Hepatitis C Treatment in Patients with Drug Injection History: Findings of the INTEGRATE Prospective, Observational Study. <i>Infectious Diseases and Therapy</i> , 2017, 6, 265-275.	1.8	5
57	Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse. <i>Journal of Clinical Virology</i> , 2017, 92, 32-38.	1.6	32
58	Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis – A pooled analysis. <i>Journal of Hepatology</i> , 2017, 67, 700-707.	1.8	11
59	SB 9200, a novel agonist of innate immunity, shows potent antiviral activity against resistant HCV variants. <i>Journal of Medical Virology</i> , 2017, 89, 1620-1628.	2.5	21
60	New metrics for the Lancet Standing Commission on Liver Disease in the UK. <i>Lancet, The</i> , 2017, 389, 2053-2080.	6.3	33
61	Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study. <i>International Journal of Drug Policy</i> , 2017, 47, 177-186.	1.6	13
62	Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study. <i>International Journal of Drug Policy</i> , 2017, 47, 230-238.	1.6	28
63	Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 805-813.	3.7	22
64	Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries. <i>Journal of Hepatology</i> , 2017, 67, 1348-1350.	1.8	31
65	Editorial for “Supplement on Optimal Therapy for Chronic Hepatitis B in China” <i>Journal of Viral Hepatitis</i> , 2017, 24, 3-3.	1.0	0
66	Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs. <i>International Journal of Drug Policy</i> , 2017, 47, 51-60.	1.6	54
67	Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study. <i>BMC Infectious Diseases</i> , 2017, 17, 420.	1.3	6
68	Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 421-430.e6.	2.4	72
69	Stage of disease in hepatitis B virus infection in Zambian adults is associated with large cell change but not well defined using classic biomarkers. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2017, 111, 425-432.	0.7	3
70	Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response. <i>PLoS ONE</i> , 2017, 12, e0168713.	1.1	6
71	Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study. <i>Annals of Gastroenterology</i> , 2017, 30, 327-343.	0.4	6
72	Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials. <i>Annals of Hepatology</i> , 2016, 15, 333-349.	0.6	1

#	ARTICLE	IF	CITATIONS
73	IL28B genotype is associated with cirrhosis or transition to cirrhosis in treatment-naive patients with chronic HCV genotype 1 infection: the international observational Gen-C study. SpringerPlus, 2016, 5, 1990.	1.2	11
74	Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort. PLoS ONE, 2016, 11, e0151703.	1.1	5
75	Systemic Inflammatory Response Syndrome After Major Abdominal Surgery Predicted by Early Upregulation of TLR4 and TLR5. Annals of Surgery, 2016, 263, 1028-1037.	2.1	41
76	Open-label study of faldaprevir plus peginterferon and ribavirin in hepatitis C virus genotype 1-infected patients who failed placebo plus peginterferon and ribavirin. Journal of Viral Hepatitis, 2016, 23, 227-231.	1.0	0
77	Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. Journal of Hepatology, 2016, 65, 741-747.	1.8	351
78	Hepatosplenic schistosomiasis is characterised by high blood markers of translocation, inflammation and fibrosis. Liver International, 2016, 36, 145-150.	1.9	15
79	Sofosbuvir and Velpatasvir for Patients with HCV Infection. New England Journal of Medicine, 2016, 374, 1687-1689.	13.9	20
80	A randomized, controlled study of peginterferon lambda-1a/ribavirin±Aadaclatasvir for hepatitis C virus genotype 2 or 3. SpringerPlus, 2016, 5, 1365.	1.2	8
81	Quantification methods for human and large animal leukocytes using DNA dyes by flow cytometry. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2016, 89, 565-574.	1.1	11
82	The Journal Of Viral Hepatitis 2016. Journal of Viral Hepatitis, 2016, 23, 4-4.	1.0	0
83	Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials. Clinical Infectious Diseases, 2016, 63, 1479-1481.	2.9	81
84	Second generation direct-acting antivirals – Do we expect major improvements?. Journal of Hepatology, 2016, 65, S130-S142.	1.8	35
85	Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials. Clinical Infectious Diseases, 2016, 63, 1042-1048.	2.9	56
86	Characteristics, Diagnosis and Prognosis of Acute-on-Chronic Liver Failure in Cirrhosis Associated to Hepatitis B.. Scientific Reports, 2016, 6, 25487.	1.6	125
87	Retrospective hepatitis C seroprevalence screening in the antenatal setting – should we be screening antenatal women?. BMJ Open, 2016, 6, e010661.	0.8	14
88	Community nurse-led initiation of antiviral therapy for chronic hepatitis C in people who inject drugs does not increase uptake of or adherence to treatment. European Journal of Gastroenterology and Hepatology, 2016, 28, 1258-1263.	0.8	7
89	Reply to: –High mortality during direct acting antiviral therapy for hepatitis C patients with Child’s C cirrhosis: Results of the Irish Early Access Programme. Journal of Hepatology, 2016, 65, 448.	1.8	0
90	Randomised controlled trial of GP-led in-hospital management of homeless people ( –Pathway™). Clinical Medicine, 2016, 16, 223-229.	0.8	36

#	ARTICLE	IF	CITATIONS
91	Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation. <i>Journal of Hepatology</i> , 2016, 65, 17-25.	1.8	157
92	Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. <i>Journal of Hepatology</i> , 2016, 64, 1224-1231.	1.8	425
93	Combination of Tenofovir Disoproxil Fumarate and Peginterferon $\alpha$ -2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B. <i>Gastroenterology</i> , 2016, 150, 134-144.e10.	0.6	284
94	Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use. <i>Journal of Hepatology</i> , 2016, 64, 234-238.	1.8	85
95	An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1). <i>PLoS ONE</i> , 2016, 11, e0158526.	1.1	4
96	Interferon Alpha Induces Sustained Changes in NK Cell Responsiveness to Hepatitis B Viral Load Suppression In Vivo. <i>PLoS Pathogens</i> , 2016, 12, e1005788.	2.1	54
97	The <i>Centrifugal Blood Pump as a Benchmark for In Vitro Testing of Hemocompatibility in Implantable Ventricular Assist Devices</i> . <i>Artificial Organs</i> , 2015, 39, 93-101.	1.0	59
98	Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection. <i>Hepatology</i> , 2015, 62, 1013-1023.	3.6	46
99	Response from Hepatitis C Trust, BASL, BIA, BVHG, BSG, and BHIVA to article asking whether widespread screening for hepatitis C is justified. <i>BMJ</i> , The, 2015, 350, h998-h998.	3.0	2
100	Implementation of the Lancet Standing Commission on Liver Disease in the UK. <i>Lancet</i> , The, 2015, 386, 2098-2111.	6.3	76
101	Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. <i>New England Journal of Medicine</i> , 2015, 373, 2608-2617.	13.9	740
102	STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection. <i>Journal of Hepatology</i> , 2015, 62, 1246-1255.	1.8	19
103	Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin. <i>Journal of Hepatology</i> , 2015, 62, 294-302.	1.8	22
104	Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE study. <i>Liver International</i> , 2015, 35, 448-454.	1.9	6
105	Shorter treatments for hepatitis C: another step forward?. <i>Lancet</i> , The, 2015, 385, 1054-1055.	6.3	4
106	Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. <i>Journal of Hepatology</i> , 2015, 62, 533-540.	1.8	161
107	Assessment of Bone Mineral Density in Tenofovir-Treated Patients With Chronic Hepatitis B: Can the Fracture Risk Assessment Tool Identify Those at Greatest Risk?. <i>Journal of Infectious Diseases</i> , 2015, 211, 374-382.	1.9	75
108	Illness perceptions and explanatory models of viral hepatitis B & C among immigrants and refugees: a narrative systematic review. <i>BMC Public Health</i> , 2015, 15, 151.	1.2	42

#	ARTICLE	IF	CITATIONS
109	Association of baseline vitamin D levels with clinical parameters and treatment outcomes in chronic hepatitis B. <i>Journal of Hepatology</i> , 2015, 63, 1086-1092.	1.8	49
110	Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon-Alfa in Patients With Hepatitis C Virus Genotype 3 Infection and Treatment-Experienced Patients With Cirrhosis and Hepatitis C Virus Genotype 2 Infection. <i>Gastroenterology</i> , 2015, 149, 1462-1470.	0.6	214
111	Informing the design of a national screening and treatment programme for chronic viral hepatitis in primary care: qualitative study of at-risk immigrant communities and healthcare professionals. <i>BMC Health Services Research</i> , 2015, 15, 97.	0.9	29
112	Development and validation of a "capture-fusion" model to study drug sensitivity of patient-derived hepatitis C. <i>Hepatology</i> , 2015, 61, 1192-1204.	3.6	5
113	Mutant Ninja viruses. <i>Hepatology</i> , 2015, 61, 421-423.	3.6	1
114	Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy. <i>Journal of Hepatology</i> , 2015, 62, 41-47.	1.8	59
115	Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. <i>Lancet, The</i> , 2014, 384, 1953-1997.	6.3	492
116	Journal of Viral Hepatitis commencing January 2015. <i>Journal of Viral Hepatitis</i> , 2014, 21, 457-457.	1.0	0
117	The Effect of Shear Stress on the Size, Structure, and Function of Human von Willebrand Factor. <i>Artificial Organs</i> , 2014, 38, 741-750.	1.0	45
118	World Gastroenterology Organisation Global Guidelines. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 204-217.	1.1	10
119	Hepatitis C genotype 1. <i>Current Opinion in Infectious Diseases</i> , 2014, 27, 535-539.	1.3	0
120	Hepatitis C triple therapy in the near future: New opportunities to cure. <i>Journal of Hepatology</i> , 2014, 61, 1192.	1.8	0
121	Extended duration therapy with pegylated interferon and ribavirin for patients with genotype 3 hepatitis C and advanced fibrosis: Final results from the STEPS trial. <i>Journal of Hepatology</i> , 2014, 60, 699-705.	1.8	15
122	Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1. <i>New England Journal of Medicine</i> , 2014, 370, 222-232.	13.9	262
123	Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection. <i>New England Journal of Medicine</i> , 2014, 370, 1889-1898.	13.9	1,580
124	Simeprevir Increases Rate of Sustained Virologic Response Among Treatment-Experienced Patients With HCV Genotype-1 Infection: A Phase IIb Trial. <i>Gastroenterology</i> , 2014, 146, 430-441.e6.	0.6	217
125	Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2014, 384, 403-413.	6.3	431
126	Ethnicity and the diagnosis gap in liver disease: a population-based study. <i>British Journal of General Practice</i> , 2014, 64, e694-e702.	0.7	39



#	ARTICLE	IF	CITATIONS
127	Modeling the impact of early antiretroviral therapy for adults coinfecting with HIV and hepatitis B or C in South Africa. <i>Aids</i> , 2014, 28, S35-S46.	1.0	23
128	The prevalence of hepatitis C virus among people of South Asian origin in Glasgow – Results from a community based survey and laboratory surveillance. <i>Travel Medicine and Infectious Disease</i> , 2013, 11, 301-309.	1.5	11
129	Clinical management of drug-drug interactions in HCV therapy: Challenges and solutions. <i>Journal of Hepatology</i> , 2013, 58, 792-800.	1.8	100
130	Development of a radial ventricular assist device using numerical predictions and experimental haemolysis. <i>Medical Engineering and Physics</i> , 2013, 35, 1197-1203.	0.8	5
131	Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failure. <i>Journal of Hepatology</i> , 2013, 58, 488-494.	1.8	19
132	Reply to: ‘‘Usefulness of Lead-In phase in determining risk/benefit of telaprevir treatment in patients with HCV cirrhosis’’. <i>Journal of Hepatology</i> , 2013, 58, 1260.	1.8	0
133	Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure. <i>Journal of Hepatology</i> , 2013, 58, 883-889.	1.8	52
134	Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial. <i>Hepatology</i> , 2013, 58, 1897-1906.	3.6	21
135	Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin. <i>Journal of Viral Hepatitis</i> , 2013, 20, e115-23.	1.0	15
136	Influencing Factors on the Outcome and Prognosis of Patients With HBV Infection: Seven Years Follow-up. <i>Hepatitis Monthly</i> , 2013, 13, e8743.	0.1	10
137	A cross sectional study of colonic diverticulosis in the London Bangladeshi population. <i>United European Gastroenterology Journal</i> , 2013, 1, 191-197.	1.6	8
138	Stat2 loss leads to cytokine-independent, cell-mediated lethality in LPS-induced sepsis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 8656-8661.	3.3	35
139	The Evaluation of Leukocytes in Response to the In Vitro Testing of Ventricular Assist Devices. <i>Artificial Organs</i> , 2013, 37, 793-801.	1.0	21
140	Telaprevir: evidence and guidance for use in clinical practice. <i>Clinical Practice (London, England)</i> , 2013, 10, 265-273.	0.1	0
141	Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. <i>Hepatology</i> , 2013, 58, 1598-1609.	3.6	431
142	Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3. <i>Gut</i> , 2012, 61, 128-134.	6.1	76
143	Efficacy and safety of telaprevir in patients with genotype 1 hepatitis C infection. <i>Therapeutic Advances in Gastroenterology</i> , 2012, 5, 139-151.	1.4	28
144	Hepatitis C prevalence in England remains low and varies by ethnicity: an updated evidence synthesis. <i>European Journal of Public Health</i> , 2012, 22, 187-192.	0.1	79

#	ARTICLE	IF	CITATIONS
145	Managing Diabetes in Patients with Chronic Liver Disease. <i>Postgraduate Medicine</i> , 2012, 124, 130-137.	0.9	28
146	Endothelin-1 as a Mediator and Potential Biomarker for Interferon Induced Pulmonary Toxicity. <i>Pulmonary Circulation</i> , 2012, 2, 501-504.	0.8	19
147	Randomized clinical trial. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 543-550.	0.8	6
148	Reevaluation of the Harboe Assay as a Standardized Method of Assessment for the Hemolytic Performance of Ventricular Assist Devices. <i>Artificial Organs</i> , 2012, 36, 724-730.	1.0	19
149	Hepatitis C infection, antiviral treatment and mental health: A European expert consensus statement. <i>Journal of Hepatology</i> , 2012, 57, 1379-1390.	1.8	194
150	An orally available, small-molecule interferon inhibits viral replication. <i>Scientific Reports</i> , 2012, 2, 259.	1.6	42
151	Preserved T-Cell Function in Children and Young Adults With Immune-Tolerant Chronic Hepatitis B. <i>Gastroenterology</i> , 2012, 143, 637-645.	0.6	257
152	Second generation direct antivirals and the way to interferon-free regimens in chronic HCV. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 471-485.	1.0	11
153	HCV genotype-3a T cell immunity: specificity, function and impact of therapy. <i>Gut</i> , 2012, 61, 1589-1599.	6.1	15
154	Triple combination treatment for chronic hepatitis C with Protease Inhibitors, pegylated interferon and ribavirin: "Lead-in" or no lead-in <sup>TM</sup> ?. <i>Liver International</i> , 2012, 32, 61-63.	1.9	2
155	Pharmacology and therapeutic potential of interferons. , 2012, 135, 44-53.		143
156	Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. <i>Hepatology</i> , 2012, 55, 49-57.	3.6	194
157	The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. <i>Hepatology</i> , 2012, 55, 749-758.	3.6	108
158	Steatosis Is an Independent Predictor of Relapse Following Rapid Virologic Response in Patients With HCV Genotype 3. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 688-693.	2.4	47
159	Telaprevir for Retreatment of HCV Infection. <i>New England Journal of Medicine</i> , 2011, 364, 2417-2428.	13.9	1,466
160	Telaprevir Alone or With Peginterferon and Ribavirin Reduces HCV RNA in Patients With Chronic Genotype 2 but Not Genotype 3 Infections. <i>Gastroenterology</i> , 2011, 141, 881-889.e1.	0.6	164
161	Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. <i>Journal of Hepatology</i> , 2011, 54, 1137-1144.	1.8	199
162	Prevalence and Risk Factors of Asymptomatic Hepatitis C Virus Infection in Bangladesh. <i>Journal of Clinical and Experimental Hepatology</i> , 2011, 1, 13-16.	0.4	18

#	ARTICLE	IF	CITATIONS
163	Response to antiviral therapy in patients with genotype 3 chronic hepatitis C. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 23, 747-753.	0.8	16
164	Insulin resistance is independently associated with significant hepatic fibrosis in Asian chronic hepatitis C genotype 2 or 3 patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 1182-1188.	1.4	18
165	Other liver viruses. <i>Medicine</i> , 2011, 39, 561-563.	0.2	0
166	Therapy for chronic viral hepatitis: current indications, optimal therapies and delivery of care. <i>Clinical Medicine</i> , 2011, 11, 184-189.	0.8	2
167	Global hepatitis, migration and its impact on Western healthcare. <i>Gut</i> , 2010, 59, 1009-1011.	6.1	24
168	Pegylated Interferons for the Treatment of Chronic Hepatitis C. <i>Drugs</i> , 2010, 70, 147-165.	4.9	91
169	Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. <i>Blood</i> , 2010, 116, 2875-2883.	0.6	79
170	<i>Cryptosporidium parvum</i> Infection Rapidly Induces a Protective Innate Immune Response Involving Type I Interferon. <i>Journal of Infectious Diseases</i> , 2009, 200, 1548-1555.	1.9	56
171	Recent advances in viral hepatitis. <i>Clinical Medicine</i> , 2009, 9, 613-616.	0.8	6
172	Quality of life considerations for patients with chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2009, 16, 605-611.	1.0	90
173	Injecting drug users with chronic hepatitis C: should they be offered antiviral therapy?. <i>Addiction</i> , 2008, 103, 1412-1413.	1.7	19
174	Advances in the diagnosis and treatment of hepatitis B. <i>Current Opinion in Infectious Diseases</i> , 2008, 21, 508-515.	1.3	12
175	Hepatitis C virus therapy to date. <i>Antiviral Therapy</i> , 2008, 13 Suppl 1, 3-8.	0.6	19
176	Hepatitis C virus therapy to date. <i>Antiviral Therapy</i> , 2008, 13, 3-8.	0.6	60
177	Directed evolution of gene-shuffled IFN- $\lambda$ molecules with activity profiles tailored for treatment of chronic viral diseases. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 8269-8274.	3.3	32
178	IFN- $\lambda$ 2 Induces Leukocyte Integrin Redistribution, Increased Adhesion, and Migration. <i>Journal of Interferon and Cytokine Research</i> , 2007, 27, 291-304.	0.5	11
179	Chronic Exposure to <i>Helicobacter pylori</i> Impairs Dendritic Cell Function and Inhibits Th1 Development. <i>Infection and Immunity</i> , 2007, 75, 810-819.	1.0	85
180	Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin. <i>Scandinavian Journal of Gastroenterology</i> , 2007, 42, 247-255.	0.6	48

#	ARTICLE	IF	CITATIONS
181	The way forward in HCV treatment – finding the right path. <i>Nature Reviews Drug Discovery</i> , 2007, 6, 991-1000.	21.5	267
182	Interferons at age 50: past, current and future impact on biomedicine. <i>Nature Reviews Drug Discovery</i> , 2007, 6, 975-990.	21.5	970
183	Interferon Proteins: Structure, Production and Purification. , 2006, , 73-83.		0
184	Health-related quality of life before, during and after combination therapy with interferon and ribavirin in unselected Swedish patients with chronic hepatitis C. <i>Scandinavian Journal of Gastroenterology</i> , 2006, 41, 577-585.	0.6	28
185	Qualitatively distinct patterns of cytokines are released by human dendritic cells in response to different pathogens. <i>Immunology</i> , 2005, 116, 245-254.	2.0	47
186	Dengue Virus Inhibits Alpha Interferon Signaling by Reducing STAT2 Expression. <i>Journal of Virology</i> , 2005, 79, 5414-5420.	1.5	227
187	Apoptotic cell death: the caspase-cleavage –gold rush–. <i>Lancet, The</i> , 2005, 365, 1293-1294.	6.3	4
188	Prevalence of Hepatitis C–Related Cirrhosis in Elderly Asian Patients Infected in Childhood. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 910-917.	2.4	37
189	Type I interferons and the innate immune response–more than just antiviral cytokines. <i>Molecular Immunology</i> , 2005, 42, 869-877.	1.0	99
190	Diagnosis and Treatment of Hepatitis C. <i>Journal of the Royal Society of Medicine</i> , 2004, 97, 223-225.	1.1	12
191	Past, Present, and Future Hepatitis C Treatments. <i>Seminars in Liver Disease</i> , 2004, 24, 97-104.	1.8	60
192	Herpes Simplex Virus Type-1-Induced Activation of Myeloid Dendritic Cells: The Roles of Virus Cell Interaction and Paracrine Type I IFN Secretion. <i>Journal of Immunology</i> , 2004, 173, 4108-4119.	0.4	79
193	Pegylated interferons. <i>Journal of Drug Evaluation</i> , 2004, 2, 113-127.	0.0	1
194	IFN-± Subtypes Differentially Affect Human T Cell Motility. <i>Journal of Immunology</i> , 2004, 173, 1663-1670.	0.4	68
195	Diagnosis and treatment of chronic hepatitis B. <i>Journal of the Royal Society of Medicine</i> , 2004, 97, 318-321.	1.1	23
196	Pegylated interferons: chemical and clinical differences. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 825-830.	1.9	97
197	Telomere Erosion in Memory T Cells Induced by Telomerase Inhibition at the Site of Antigenic Challenge In Vivo. <i>Journal of Experimental Medicine</i> , 2004, 199, 1433-1443.	4.2	107
198	Combination therapy with amantadine and interferon in naïve patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials. <i>Journal of Hepatology</i> , 2004, 40, 478-483.	1.8	38

#	ARTICLE	IF	CITATIONS
199	Corrigendum to "Mechanisms of action of interferon and nucleoside analogues" [J Hepatol 39 (2003) S93-S98]. Journal of Hepatology, 2004, 40, 364.	1.8	1
200	Diagnosis and Treatment of Chronic Hepatitis B. Journal of the Royal Society of Medicine, 2004, 97, 318-321.	1.1	16
201	Diagnosis and treatment of hepatitis C. Journal of the Royal Society of Medicine, 2004, 97, 223-225.	1.1	11
202	Evaluation of a modified commercial assay in detecting antibody to hepatitis C virus in oral fluids and dried blood spots. Journal of Medical Virology, 2003, 71, 49-55.	2.5	152
203	Pegylated interferon with ribavirin therapy for chronic infection with the hepatitis C virus. Expert Opinion on Pharmacotherapy, 2003, 4, 685-691.	0.9	18
204	Mechanisms of action of interferon and nucleoside analogues. Journal of Hepatology, 2003, 39, 93-98.	1.8	63
205	High yield expression, refolding, and characterization of recombinant interferon $\lambda 2/\lambda 8$ hybrids in Escherichia coli. Protein Expression and Purification, 2003, 31, 222-230.	0.6	16
206	Activity of Hybrid Type I Interferons in Cells Lacking Tyk2: A Common Region of IFN- $\lambda 2/8$ Induces a Response, but IFN- $\lambda 2/8$ Hybrids Can Behave Like IFN- $\lambda 2$ . Journal of Interferon and Cytokine Research, 2003, 23, 655-666.	0.5	10
207	DIFFERENT ACTIVITIES OF TYPE I INTERFERONS ON HEPATITIS B VIRUS CORE PROMOTER REGULATED TRANSCRIPTION. Cytokine, 2002, 17, 214-220.	1.4	5
208	Management of chronic hepatitis C - time for a change?. Journal of Viral Hepatitis, 2002, 9, 82-83.	1.0	1
209	Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology, 2002, 35, 433-439.	3.6	407
210	Interferon plus amantadine versus interferon alone in the treatment of naïve patients with chronic hepatitis C: a UK multicentre study. Journal of Hepatology, 2001, 35, 512-516.	1.8	26
211	Evidence for a cerebral effect of the hepatitis C virus. Lancet, The, 2001, 358, 38-39.	6.3	316
212	Selection of HCV NS5A quasispecies during IFN therapy in patients with chronic HCV. Digestive Diseases and Sciences, 2001, 46, 1399-1408.	1.1	4
213	Secretion of human hepatitis B virus is inhibited by the imino sugar N-butyldeoxynojirimycin (antivirals/glycosylation). World Scientific Series in 20th Century Biology, 2000, , 552-556.	0.1	0
214	Human Type I Interferons Differ Greatly in Their Effects on the Proliferation of Primary B Cells. Journal of Interferon and Cytokine Research, 1999, 19, 309-318.	0.5	44
215	Hepatitis C virus NS5A protein inhibits interferon antiviral activity, but the effects do not correlate with clinical response. Gastroenterology, 1999, 117, 1187-1197.	0.6	86
216	Spontaneous seroconversion in chronic hepatitis B: role of mutations in the precore/core gene. Digestive Diseases and Sciences, 1998, 43, 1714-1718.	1.1	2

#	ARTICLE	IF	CITATIONS
217	Interferons in Host Defense. Seminars in Liver Disease, 1997, 17, 287-295.	1.8	46
218	Increase in primary liver cancer in the UK, 1979-1994. Lancet, The, 1997, 350, 1142-1143.	6.3	490
219	The relationship of histology to genotype in chronic HCV infection. Liver, 1997, 17, 144-151.	0.1	21
220	Characterization of Î²-R1, a Gene That Is Selectively Induced by Interferon Î² (IFN-Î²) Compared with IFN-Î±. Journal of Biological Chemistry, 1996, 271, 22878-22884.	1.6	168
221	Reversible AIDS-related sclerosing cholangitis. Journal of Hepatology, 1995, 23, 209-211.	1.8	7
222	Treatment of Hepatitis C with Interferon: Mechanism of Action of Interferon. , 1994, , 594-600.		1
223	Expression of the terminal protein of hepatitis B virus is associated with failure to respond to interferon therapy. Hepatology, 1993, 17, 757-762.	3.6	25
224	Inhibition of the cellular response to interferons by products of the adenovirus type 5 E1A oncogene. Nucleic Acids Research, 1991, 19, 4387-4393.	6.5	119
225	Serum F protein: A new sensitive and specific test of hepatocellular damage. Clinica Chimica Acta, 1989, 184, 85-92.	0.5	22
226	Hepatitis B and C Viruses- How do They Affect Management of IBD?. , 0, , 142-145.		0
227	HBeAg-Negative Chronic Hepatitis B Infection with Abnormal Transaminases and Minimal Changes on Liver Biopsy. , 0, , 135-137.		0
228	Combination Therapy for Chronic Hepatitis B Virus Infection: Should we use itab initio or Sequentially?. , 0, , 138-141.		0
229	Hepatitis B Infection in Surgeons and Healthcare Workers: What should we do to Protect Patients?. , 0, , 151-153.		0
230	Novel Interferons: Is there Life in the Old Dog Yet?. , 0, , 236-238.		0
231	Most Patients with Hepatitis C will Die from their Disease. , 0, , 246-248.		0